NervGen Pharma Corp. Archives - Matribhumi Samachar English

NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury

August 21, 2025 International

Demonstrated significant hearing restoration in blast-induced sensorineural hearing loss models Promoted significant functional recovery and axonal regeneration in peripheral nerve injury models Reinforced NVG-291’s broad therapeutic potential with new data across three distinct injury models Vancouver, British Columbia–(Newsfile Corp. – August 21, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: …

NervGen Announces Leadership Transition to Support Strategic Growth and Expansion

July 17, 2025 International

Chairman Dr. Adam Rogers Appointed Interim CEO Following Landmark Positive Chronic Spinal Cord Injury Trial Results Vancouver, British Columbia–(Newsfile Corp. – July 17, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (the “Company”), a clinical-stage biotechnology company developing innovative therapies for spinal cord injury (SCI) and other nervous system disorders, today …

Tag Archives: NervGen Pharma Corp.

NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury

NervGen Announces Leadership Transition to Support Strategic Growth and Expansion